{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T13:55:18Z","timestamp":1773150918306,"version":"3.50.1"},"reference-count":56,"publisher":"Oncology Nursing Society (ONS)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CJON"],"published-print":{"date-parts":[[2018,8,1]]},"DOI":"10.1188\/18.cjon.e103-e114","type":"journal-article","created":{"date-parts":[[2018,7,23]],"date-time":"2018-07-23T08:33:12Z","timestamp":1532334792000},"page":"E103-E114","source":"Crossref","is-referenced-by-count":8,"title":["Brentuximab Vedotin: A Nursing Perspective on Best Practices and Management of Associated Adverse Events"],"prefix":"10.1188","volume":"22","author":[{"given":"Kathleen","family":"Clifford","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda","family":"Copeland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory","family":"Knutzen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ellen","family":"Samuelson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurie","family":"Grove","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Schiavo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1302","published-online":{"date-parts":[[2018,8,1]]},"reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"Allen J.T., & Spiteri, M.A. (2002). Growth factors in idiopathic pulmonary fibrosis: Relative roles. Respiratory Research, 3, 13.","DOI":"10.1186\/rr162"},{"key":"2","doi-asserted-by":"crossref","unstructured":"Ansell, S.M. (2016). Hodgkin lymphoma: 2016 update on diagnosis, risk-stratification, and management. American Journal of Hematology, 91, 434\u2013442. https:\/\/doi.org\/10.1002\/ajh.24272","DOI":"10.1002\/ajh.24272"},{"key":"3","doi-asserted-by":"crossref","unstructured":"Arora, A., Bhatt, V.R., Liewer, S., Armitage, J.O., & Bociek, R.G. (2015). Brentuximab vedotin desensitization in a patient with refractory Hodgkin\u2019s lymphoma. European Journal of Haematology, 95, 361\u2013364. https:\/\/doi.org\/10.1111\/ejh.12570","DOI":"10.1111\/ejh.12570"},{"key":"4","unstructured":"Boussios, S., Pentheroudakis, G., Katsanos, K., & Pavlidis, N. (2012). Systemic treatment-induced gastrointestinal toxicity: Incidence, clinical presentation and management. Annals of Gastroenterology, 25, 106\u2013118."},{"key":"5","doi-asserted-by":"crossref","unstructured":"Bupathi, M., Hajjar, J., Bean, S., Fu, S., Hong, D., Karp, D., . . . Naing, A. (2017). Incidence of infusion reactions to anti-neoplastic agents in early phase clinical trials: The MD Anderson Cancer Center experience. Investigational New Drugs, 35, 59\u201367. https:\/\/doi.org\/10.1007\/s10637-016-0395-y","DOI":"10.1007\/s10637-016-0395-y"},{"key":"6","doi-asserted-by":"crossref","unstructured":"Chen, R., Gopal, A.K., Smith, S.E., Ansell, S.M., Rosenblatt, J.D., Savage, K.J., . . . Younes, A. (2016). Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma. Blood, 128, 1562\u20131566. https:\/\/doi.org\/10.1182\/blood-2016-02-699850","DOI":"10.1182\/blood-2016-02-699850"},{"key":"7","unstructured":"Center for Drug Evaluation and Research. (2011). Adcetris\u00ae (brentuximab vedotin) [Application Number 125399Orig1s000]. Retrieved from https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2011\/125399Orig1s000A..."},{"key":"8","doi-asserted-by":"crossref","unstructured":"DeVita, M.D., Evens, A.M., Rosen, S.T., Greenberger, P.A., & Petrich, A.M. (2014). Multiple successful desensitizations to brentuximab vedotin: A case report and literature review. Journal of the National Comprehensive Cancer Network, 12, 465\u2013471.","DOI":"10.6004\/jnccn.2014.0052"},{"key":"9","doi-asserted-by":"crossref","unstructured":"Donohue, R. (2006). Development and implementation of a risk assessment tool for chemotherapy-induced neutropenia. Oncology Nursing Forum, 33, 347\u2013352. https:\/\/doi.org\/10.1188\/06.ONF.347-352","DOI":"10.1188\/06.ONF.347-352"},{"key":"10","doi-asserted-by":"crossref","unstructured":"Fanale, M.A., Forero-Torres, A., Rosenblatt, J.D., Advani, R.H., Franklin, A.R., Kennedy, D.A., . . . Bartlett, N.L. (2012). A phase I weekly dosing study of brentuximab vedotin in patients with relapsed\/refractory CD30-positive hematologic malignancies. Clinical Cancer Research, 18, 248\u2013255. https:\/\/doi.org\/10.1158\/1078-0432.CCR-11-1425","DOI":"10.1158\/1078-0432.CCR-11-1425"},{"key":"11","doi-asserted-by":"crossref","unstructured":"Finnes, H.D., Chaffee, K.G., Call, T.G., Ding, W., Kenderian, S.S., Bowen, D.A., . . . Parikh S.A. (2017). Pharmacovigilance during ibrutinib therapy for chronic lymphocytic leukemia (CLL)\/small lymphocytic lymphoma (SLL) in routine clinical practice. Leukemia and Lymphoma, 58, 1376\u20131383. https:\/\/doi.org\/10.1080\/10428194.2016.1251592","DOI":"10.1080\/10428194.2016.1251592"},{"key":"12","doi-asserted-by":"crossref","unstructured":"Fizesan, M., Boin, C., Aujoulat, O., Newinger, G., Ghergus, D., Watier, H., . . . Ojeda-Uribe, M. (2016). Successful rapid desensitization to the antibody-drug conjugate brentuximab vedotin in a patient with refractory Hodgkin lymphoma. Journal of Oncology Pharmacy Practice, 22, 188\u2013192. https:\/\/doi.org\/10.1177\/1078155214567164","DOI":"10.1177\/1078155214567164"},{"key":"13","doi-asserted-by":"crossref","unstructured":"Forero-Torres, A., Bartlett, N.L., Berryman, R.B., Chen, R., Matous, J.V., Fanale, M.A., . . . Gopal, A.K. (2015). Extended treatment with brentuximab vedotin in patients with relapsed or refractory CD30-positive hematological malignancies. Leukemia and Lymphoma, 56, 1151\u20131153. https:\/\/doi.org\/10.3109\/10428194.2014.951843","DOI":"10.3109\/10428194.2014.951843"},{"key":"14","doi-asserted-by":"crossref","unstructured":"Forero-Torres, A., Holkova, B., Goldschmidt, J., Chen, R., Olsen, G., Boccia, R.V., . . . Yasenchak, C.A. (2015). Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older. Blood, 126, 2798\u20132804. https:\/\/doi.org\/10.1182\/blood-2015-06-644336","DOI":"10.1182\/blood-2015-06-644336"},{"key":"15","doi-asserted-by":"crossref","unstructured":"Freifeld, A.G., Bow, E.J., Sepkowitz, K.A., Boeckh, M.J., Ito, J.I., Mullen, C.A., . . . Wingard, J.R. (2011). Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clinical Infectious Diseases, 52, e56\u2013e93. https:\/\/doi.org\/10.1093\/cid\/cir073","DOI":"10.1093\/cid\/cir073"},{"key":"16","doi-asserted-by":"crossref","unstructured":"Gandhi, M.D., Evens, A.M., Fenske, T.S., Hamlin, P., Coiffier, B., Engert, A., . . . Winter, J.N. (2014). Pancreatitis in patients treated with brentuximab vedotin: A previously unrecognized serious adverse event. Blood, 123, 2895\u20132897. https:\/\/doi.org\/10.1182\/blood-2014-03-561878","DOI":"10.1182\/blood-2014-03-561878"},{"key":"17","doi-asserted-by":"crossref","unstructured":"Gardai, S.J., Epp, A., & Law, C.L. (2015) Brentuximab vedotin-mediated immunogenic cell death. Cancer Research, 75(Suppl. 15), Abstract 2469. https:\/\/doi.org\/10.1158\/1538-7445.AM2015-2469","DOI":"10.1158\/1538-7445.AM2015-2469"},{"key":"18","doi-asserted-by":"crossref","unstructured":"Gascoyne, R.D., Aoun, P., Wu, D., Chhanabhai, M., Skinnider, B.F., Greiner, T.C., . . . Weisenburger, D.D. (1999). Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. Blood, 93, 3913\u20133921.","DOI":"10.1182\/blood.V93.11.3913"},{"key":"19","doi-asserted-by":"crossref","unstructured":"Han, T.H., Gopal, A.K., Ramchandren, R., Goy, A., Chen, R., Matous, J.V., . . . O\u2019Connor, O.A. (2013). CYP3A-mediated drug-drug interaction potential and excretion of brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive hematologic malignancies. Journal of Clinical Pharmacology, 53, 866\u2013877. https:\/\/doi.org\/10.1002\/jcph.116","DOI":"10.1002\/jcph.116"},{"key":"20","doi-asserted-by":"crossref","unstructured":"Han, X., Wang, L., Shi, H., Zheng, G., He, J., Wu, W., . . . Cai, Z. (2017). Acupuncture combined with methylcobalamin for the treatment of chemotherapy-induced peripheral neuropathy in patients with multiple myeloma. BMC Cancer, 17, 40. https:\/\/doi.org\/10.1186\/s12885-016-3037-z","DOI":"10.1186\/s12885-016-3037-z"},{"key":"21","doi-asserted-by":"crossref","unstructured":"Hershman, D.L., Lacchetti, C., Dworkin, R.H., Lavoie Smith, E.M., Bleeker, J., Cavaletti, G., . . . Loprinzi, C.L. (2014). Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. Journal of Clinical Oncology, 32, 1941\u20131967. https:\/\/doi.org\/10.1200\/JCO.2013.54.0914","DOI":"10.1200\/JCO.2013.54.0914"},{"key":"22","doi-asserted-by":"crossref","unstructured":"Hollander, P., Rostgaard, K., Smedby, K.E., Change, E.T., Amini, R.M., de Nully Brown, P., . . . Hjalgrim, H. (2015). Autoimmune and atopic disorders and risk of classical Hodgkin lymphoma. American Journal of Epidemiology, 182, 624\u2013632. https:\/\/doi.org\/10.1093\/aje\/kwv081","DOI":"10.1093\/aje\/kwv081"},{"key":"23","doi-asserted-by":"crossref","unstructured":"Kullak-Ublick, G.A., Andrade, R.J., Merz, M., End, P., Benesic, A., Gerbes, A.L., & Aithal G.P. (2017). Drug-induced liver injury: Recent advances in diagnosis and risk assessment. Gut, 66, 1154\u20131164. https:\/\/doi.org\/10.1136\/gutjnl-2016-313369","DOI":"10.1136\/gutjnl-2016-313369"},{"key":"24","doi-asserted-by":"crossref","unstructured":"Li, F., Emmerton, K.K., Jonas, M., Zhang, X., Miyamoto, J.B., Setter, J.R., . . . Law, C.L. (2016). Intracellular released payload influences potency and bystander-killing effects of antibody-drug conjugates in preclinical models. Cancer Research, 76, 2710\u20132719. https:\/\/doi.org\/10.1158\/0008-5472.CAN-15-1795","DOI":"10.1158\/0008-5472.CAN-15-1795"},{"key":"25","doi-asserted-by":"crossref","unstructured":"Macalalad, A.R., McAuliffe, M., Yang, H., Kageleiry, A., Zhong, Y., Wu, E.Q., . . . Bonthapally, V. (2015). The epidemiology and targeted therapies for relapsed and refractory CD30+ lymphomas. Current Medical Research and Opinion, 31, 537\u2013545. https:\/\/doi.org\/10.1185\/03007995.2015.1008131","DOI":"10.1185\/03007995.2015.1008131"},{"key":"26","doi-asserted-by":"crossref","unstructured":"Morton, L.M., Wang, S.S., Devesa, S.S., Hartge, P., Weisenburger, D.D., & Linet, M.S. (2006). Lymphoma incidence patterns by WHO subtype in the United States, 1992\u20132001. Blood,107, 265\u2013276.","DOI":"10.1182\/blood-2005-06-2508"},{"key":"27","doi-asserted-by":"crossref","unstructured":"Moskowitz, C.H., Nademanee, A., Masszi, T., Agura, E., Holowiecki, J., Abidi, M.H., . . . Walewski, J. (2015). Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin\u2019s lymphoma at risk of relapse or progression (AETHERA): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, 385, 1853\u20131862. https:\/\/doi.org\/10.1016\/S0140-6736(15)60165-9","DOI":"10.1016\/S0140-6736(15)60165-9"},{"key":"28","doi-asserted-by":"crossref","unstructured":"M\u00fcller, P., Martin, K., Theurich, S., Schreiner, J., Savic, S., Terszowski, G., . . . Zippelius, A. (2014). Microtubule-depolymerizing agents used in antibody-drug conjugates induce antitumor immunity by stimulation of dendritic cells. Cancer Immunology Research, 2, 741\u2013755. https:\/\/doi.org\/10.1158\/2326-6066.CIR-13-0198","DOI":"10.1158\/2326-6066.CIR-13-0198"},{"key":"29","unstructured":"National Cancer Institute. (2010). Common terminology criteria for adverse events [v.4.03]. Retrieved from https:\/\/www.eortc.be\/services\/doc\/ctc\/CTCAE_4.03_2010-06-14_QuickReferen..."},{"key":"30","unstructured":"National Cancer Institute. (2018). Cancer stat facts: Hodgkin lymphoma. Retrieved from https:\/\/seer.cancer.gov\/statfacts\/html\/hodg.html"},{"key":"31","unstructured":"National Comprehensive Cancer Network. (2018a). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae): Hodgkin lymphoma [v.3.2018]. Retrieved from https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/hodgkins.pdf"},{"key":"32","unstructured":"National Comprehensive Cancer Network. (2018b). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae): Survivorship [v.3.2017]. Retrieved from https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/survivorship.pdf"},{"key":"33","doi-asserted-by":"crossref","unstructured":"Oflazoglu, E., Stone, I.J., Gordon, K.A., Grewal, I.S., van Rooijen, N., Law, C.L., & Gerber, H.P. (2007). Macrophages contribute to the antitumor activity of the anti-CD30 antibody SGN-30. Blood, 110, 4370\u20134372. https:\/\/doi.org\/10.1182\/blood-2007-06-097014","DOI":"10.1182\/blood-2007-06-097014"},{"key":"34","doi-asserted-by":"crossref","unstructured":"Paice, J.A. (2009). Clinical challenges: Chemotherapy-induced peripheral neuropathy. Seminars in Oncology Nursing, 25(2 Suppl. 1), S8\u2013S19. https:\/\/doi.org\/10.1016\/j.soncn.2009.03.013","DOI":"10.1016\/j.soncn.2009.03.013"},{"key":"35","doi-asserted-by":"crossref","unstructured":"Pro, B., Advani, R., Brice, P., Bartlett, N.L., Rosenblatt, J.D., Illidge, T., . . . Shustov, A. (2012). Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: Results of a phase II study. Journal of Clinical Oncology, 30, 2190\u20132196. https:\/\/doi.org\/10.1200\/JCO.2011.38.0402","DOI":"10.1200\/JCO.2011.38.0402"},{"key":"36","doi-asserted-by":"crossref","unstructured":"Pro, B., Advani, R.H., Brice, P., Bartlett, N.L., Rosenblatt, J.D., Illidge, T., . . . Shustov, A.R. (2016, December). Five-year survival data from a pivotal phase 2 study of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma. Paper presented at the 58th Annual Meeting and Exposition of the American Society of Hematology, Atlanta, GA.","DOI":"10.1182\/blood.V128.22.4144.4144"},{"key":"37","doi-asserted-by":"crossref","unstructured":"Quasthoff, S., & Hartung, H.P. (2002). Chemotherapy-induced peripheral neuropathy. Journal of Neurology, 249, 9\u201317.","DOI":"10.1007\/PL00007853"},{"key":"38","unstructured":"Seattle Genetics. (2018). Adcetris\u00ae (brentuximab vedotin) [Prescribing information]. Retrieved from https:\/\/adcetris.com\/pdf\/ADCETRIS-brentuximab-vedotin-Prescribing-Inform..."},{"key":"39","doi-asserted-by":"crossref","unstructured":"Saribas, A.S., Ozdemir A., Lam, C., & Safak, M. (2010). JC virus-induced progressive multifocal leukoencephalopathy. Future Virology, 5, 313\u2013323. https:\/\/doi.org\/10.2217\/fvl.10.12","DOI":"10.2217\/fvl.10.12"},{"key":"40","doi-asserted-by":"crossref","unstructured":"Shiels, M.S., Koritzinsky, E.H., Clarke, C.A., Suneja, G., Morton, L.M., & Engels, E.A. (2014). Prevalence of HIV infection among U.S. Hodgkin lymphoma cases. Cancer Epidemiology, Biomarkers and Prevention, 23, 274\u2013281. https:\/\/doi.org\/10.1158\/1055-9965.EPI-13-0865","DOI":"10.1158\/1055-9965.EPI-13-0865"},{"key":"41","unstructured":"Story, S.K., Petrov, A.A., & Geskin, L.J. (2014). Successful desensitization to brentuximab vedotin after hypersensitivity reaction. Journal of Drugs in Dermatology, 13, 749\u2013751."},{"key":"42","doi-asserted-by":"crossref","unstructured":"Sweetenham, J., Walewski, J., Nademanee, A.P., Masszi, T., Agura, E., Holowiecki, J., . . . Moskowitz, C.H. (2015, December). Updated efficacy and safety data from the AETHERA trial of consolidation with brentuximab vedotin after autologous stem cell transplant (ASCT) in Hodgkin lymphoma patients at high risk of relapse. Paper presented at the 57th Annual Meeting and Exposition of the American Society of Hematology, Orlando, FL.","DOI":"10.1182\/blood.V126.23.3172.3172"},{"key":"43","unstructured":"Takeda Pharmaceuticals. (2017). Adcetris\u00ae (brentuximab vedotin) [Prescribing information]. Retrieved from http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Info..."},{"key":"44","doi-asserted-by":"crossref","unstructured":"Tenner, S., Baillie, J., DeWitt, J., & Vege, S.S. (2013). American College of Gastroenterology guideline: Management of acute pancreatitis. American Journal of Gastroenterology, 108, 1400\u20131415. https:\/\/doi.org\/10.1038\/ajg.2013.218","DOI":"10.1038\/ajg.2013.218"},{"key":"45","doi-asserted-by":"crossref","unstructured":"Tofthagen, C. (2010). Patient perceptions associated with chemotherapy-induced peripheral neuropathy [Online exclusive]. Clinical Journal of Oncology Nursing, 14, E22\u2013E28. https:\/\/doi.org\/10.1188\/10.CJON.E22-E28","DOI":"10.1188\/10.CJON.E22-E28"},{"key":"46","doi-asserted-by":"crossref","unstructured":"Tofthagen, C., Visovsky, C.M., & Hopgood, R. (2013). Chemotherapy-induced peripheral neuropathy: An algorithm to guide nursing management. Clinical Journal of Oncology Nursing, 17, 138\u2013144. https:\/\/doi.org\/10.1188\/13.CJON.138-144","DOI":"10.1188\/13.CJON.138-144"},{"key":"47","doi-asserted-by":"crossref","unstructured":"Tomblyn, M., Chiller, T., Einsele, H., Gress, R., Sepkowitz, K., Storek, J., . . . Boeckh, M.J. (2009). Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: A global perspective. Biology of Blood and Marrow Transplantation, 15, 1143\u20131238. https:\/\/doi.org\/10.1016\/j.bbmt.2009.06.019","DOI":"10.1016\/j.bbmt.2009.06.019"},{"key":"48","doi-asserted-by":"crossref","unstructured":"Urru, S.A., Mariotti, E., Carta, P., Massidda, S., Marcias, M., Murru, R., . . . Angelucci, E. (2014). Acute pancreatitis following brentuximab vedotin therapy for refractory Hodgkin lymphoma: A case report. Drugs in R and D, 14, 9\u201311. https:\/\/doi.org\/10.1007\/s40268-014-0036-x","DOI":"10.1007\/s40268-014-0036-x"},{"key":"49","doi-asserted-by":"crossref","unstructured":"Valdivieso, M., Kujawa A.M., Jones, T., & Baker, L.H. (2012). Cancer survivors in the United States: A review of the literature and a call to action. International Journal of Medical Sciences, 9, 163\u2013173. https:\/\/doi.org\/10.7150\/ijms.3827","DOI":"10.7150\/ijms.3827"},{"key":"50","doi-asserted-by":"crossref","unstructured":"Visovsky, C., Haas, M., Faiman, B., Kurtin, S., Shaftic, A.M., Lyden, E., & Rice, J. (2012). Nurse self-evaluation of assessment of chemotherapy-induced peripheral neuropathy in patients with cancer. Journal of the Advanced Practitioner in Oncology, 3, 319\u2013325.","DOI":"10.6004\/jadpro.2012.3.5.5"},{"key":"51","doi-asserted-by":"crossref","unstructured":"Visovsky, C., Meyer, R.R., Roller, J., & Poppas, M. (2008). Evaluation and management of peripheral neuropathy in diabetic patients with cancer. Clinical Journal of Oncology Nursing, 12, 243\u2013247. https:\/\/doi.org\/10.1188\/08.CJON.243-247","DOI":"10.1188\/08.CJON.243-247"},{"key":"52","doi-asserted-by":"crossref","unstructured":"Younes, A., Bartlett, N.L., Leonard, J.P., Kennedy, D.A., Lynch, C.M., Sievers, E.L., & Forero-Torres, A. (2010). Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. New England Journal of Medicine, 363, 1812\u20131821. https:\/\/doi.org\/10.1056\/NEJMoa1002965","DOI":"10.1056\/NEJMoa1002965"},{"key":"53","doi-asserted-by":"crossref","unstructured":"Younes, A., Connors, J.M., Park, S.I., Fanale, M., O\u2019Meara, M.M., Hunder, N.N., . . . Ansell S.M. (2013). Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin\u2019s lymphoma: A phase 1, open-label, dose-escalation study. Lancet Oncology, 14, 1348\u20131356. https:\/\/doi.org\/10.1016\/S1470-2045(13)70501-1","DOI":"10.1016\/S1470-2045(13)70501-1"},{"key":"54","doi-asserted-by":"crossref","unstructured":"Younes, A., Gopal, A.K., Smith, S.E., Ansell, S.M., Rosenblatt, J.D., Savage, K.J., . . . Chen, R. (2012). Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin\u2019s lymphoma. Journal of Clinical Oncology, 30, 2183\u20132189. https:\/\/doi.org\/10.1200\/JCO.2011.38.0410","DOI":"10.1200\/JCO.2011.38.0410"},{"key":"55","doi-asserted-by":"crossref","unstructured":"Zanotti, K.M., & Markman, M. (2001). Prevention and management of antineoplastic-induced hypersensitivity reactions. Drug Safety, 24, 767\u2013779.","DOI":"10.2165\/00002018-200124100-00005"},{"key":"56","doi-asserted-by":"crossref","unstructured":"Zhao, B., Chen, R., O\u2019Connor, O.A., Gopal, A.K., Ramchandren, R., Goy, A., . . . Han, T.H. (2016). Brentuximab vedotin, an antibody\u2013drug conjugate, in patients with CD30-positive haematologic malignancies and hepatic or renal impairment. British Journal of Clinical Pharmacology, 82, 696\u2013705. https:\/\/doi.org\/10.1111\/bcp.12988","DOI":"10.1111\/bcp.12988"}],"container-title":["Clinical Journal of Oncology Nursing"],"original-title":[],"link":[{"URL":"http:\/\/cjon.ons.org\/cjon\/22\/4\/brentuximab-vedotin-nursing-perspective-best-practices-and-management-associated-adverse","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T19:51:22Z","timestamp":1763754682000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ons.org\/publications-research\/cjon\/22\/4\/brentuximab-vedotin-nursing-perspective-best-practices-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,1]]},"references-count":56,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,8,1]]}},"URL":"https:\/\/doi.org\/10.1188\/18.cjon.e103-e114","relation":{},"ISSN":["1092-1095","1538-067X"],"issn-type":[{"value":"1092-1095","type":"print"},{"value":"1538-067X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,1]]}}}